Financial Statements

Adaptimmune Therapeutics plc (ADAP)

$1.58

-0.01 (0.00%)

Cash Flow Statement

All numbers are in thousands
Year XLSX
2023
XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
Operating Cash Flow -141,426.06-141,76910,729-53,591-112,507
Net Income -114,312.37-165,456-158,090-130,092-137,165
Depreciation & Amortization 9,857.066,0756,5677,5948,010
Deferred income taxes -41,905.34-5,8162,5031,063
Stock-based compensation 11,77318,24020,62910,41411,053
Change in working capital -25,048.72-1,531134,63456,0454,717
Other non-cash items 18,210.319031,173-55-185
Investing Cash Flow 177,222.2789,13775,800-278,92494,945
Investments in PPE -4,898.91-29,740-8,781-2,906-3,074
Acquisitions 45,439.4577,8572075651,482
Investment purchases -76,247.40-48,117-139,762-381,040-27,284
Sales/Maturities of investments 211,800.79166,994224,343105,022125,303
Other Investing Activites 1,128.36-77,857-207-565-1,482
Financing Cash Flow 883.4112,8673,288340,051366
Common Stock Issuance 883.4112,8172,529334,388367.51
Other Financing Activites -507595,663-1.51
Accounts receivables -1,296-9,806.94-19,355.691,760.59-1,441.94
Accounts payables -9,122.224,405.284,206.503,897.087,634.47
Inventory -05,401.6615,149.19-5,657.67-6,192.53
Other working capital -14,630.49-1,531134,63456,0454,717
Cash at beginning of period 108,033151,66661,48454,90872,476
Cash at end of period 143,991109,602151,66661,48454,908
Capital Expenditure -4,898.91-29,740-8,781-2,906-3,074
Effect of forex changes on cash 877-2,299365-960-372
Net cash flow / Change in cash 35,958-42,06490,1826,576-17,568
Free Cash Flow -146,324.98-171,5091,948-56,497-115,581

Adaptimmune Therapeutics plc income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adaptimmune Therapeutics plc FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.